Depomed Inc

Depomed — Q3 2017 Earnings Presentation

27 slides from Depomed's earnings presentation, Nov 7, 2017

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements 2 The statements that are not historical facts contained in this presentation are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to Depomed’s strategy, plans, objectives, expectations (financial or otherwise) an

  2. Slide 2: A Clear Strategy for Growth: Three Pillars

    A Clear Strategy for Growth Not One But Three Pillars Form Our Strategy 3 MAINTAIN a Strong NUCYNTA Franchise GROW Neurology and Pain Businesses BUILD a New Specialty Business

  3. Slide 3: Principles Guiding the Way We Do Business

    Principles Guiding the Way We Do Business PUTTING the Patient First PRODUCTIVITY Aimed at Improving Effectiveness Across the Business PROFITABILITY in Line with Our Peer Group 4

  4. Slide 4: Maintain a Strong NUCYNTA Franchise

    Maintain a Strong NUCYNTA Franchise NUCYNTA ER outperformed the market by 640 bps in Q3 20171 Growth driven by PAIN Practices, accounting for ~75% of our business2 NUCYNTA ER reached all-time market share high in September NUCYNTA outperformed the market by 230 bps in Q3 20171 Growth driven by PAIN

  5. Slide 5: Grow Our Neurology and Pain Businesses

    GROW Grow Our Neurology and Pain Businesses September marked the completed relaunch of our Neurology salesforce with 90 representatives Provides proper support to highly-promotionally sensitive products Gralise® and CAMBIA ® October: Increased levels of Gralise® starter packs seen Creates credible p

  6. Slide 6: Build A New Specialty Business

    Build A New Specialty Business Establishment of a New Specialty Products Business Unit Mark Booth as General Manager brings 30+ years of biopharma experience Objective is to build a portfolio of specialty/orphan drugs addressing the unmet needs of the patient, physician and payors Provides a platfor

  7. Slide 7: Transformational Transaction Creates New Specialty Business

    Transformational Transaction Creates New Specialty Business Depomed/ Slán Medicinal Holdings Limited Acquisition of Cosyntropin (Synthetic ACTH Depo) provides a late-stage, high-value product Depomed is the exclusive licensee for United States Current U.S. market is secured by H.P. Acthar® Gel (Natu

  8. Slide 8: Established and New Leaders Bringing Valuable Experience

    Established and New Leaders Bringing Valuable Experience at Pivotal Time 9 Established Roles August Moretti SVP Finance and Chief Financial Officer Alexza, Alavita; 30+ Years Experience Matthew Gosling SVP and General Counsel Heller Ehrman; 20 Years Experience New Roles Jeff Carrol Vice President an

  9. Slide 9: Milestones Driving Growth in 2018 and Beyond

    Strategy: Unveil Enhanced NUCYNTA Go-To-Market Strategy Synthetic Cosyntropin (Synthetic ACTH Depot): Commence Investigational New Drug (IND) Trial in Infantile Spasms Purdue Litigation: Pre-Trial Conference to Set Trial Date Refinancing: Execute Refinancing of Deerfield and Pharmakon Advisors’ Secu

  10. Slide 10: Third Quarter 2017 Financial Results

    Third Quarter 2017 Financial Results August Moretti, SVP Finance and Chief Financial Officer

  11. Slide 11: Third Quarter 2017 Revenue Overview

    12 3Q 2017 total GAAP revenues of $95.4 million Financial 3Q 2017 net sales of $58.7 million versus $63.9 million in 2Q 2017 NUCYNTA® 3Q 2017 net sales of $21.1 million versus $18.1 million in 2Q 2017 Gralise® 3Q 2017 net sales of $8.2 million versus $8.5 million in 2Q 2017 CAMBIA® 3Q 2017 net sales

  12. Slide 12: Third Quarter 2017 Overview

    13 Approximately 18% of revenue; down slightly from the second quarter COGS $48.9 million GAAP SG&A $46.8 million Non-GAAP SG&A $1.8 million GAAP R&D $1.7 million Non-GAAP R&D $30.1 million versus $28.3 million in Q2 2017 Non-GAAP EBIDTA Third Quarter 2017 Overview Decreased approximately two days f

  13. Slide 13: Third Quarter 2017 Balance Sheet

    Third Quarter 2017 Balance Sheet 14 cash equivalents and marketable securities of $114 million versus $117 million in Q2 2017 Cash CONSOLIDATED CONDENSED BALANCE SHEETS (in thousands) (unaudited) September 30, December 31, 2017 2016 Cash, cash equivalents and marketable securities 113,457 $ 177,420

  14. Slide 14: Updated Full-Year Guidance

    Updated Full-Year Guidance Updated Guidance Prior Guidance Total Revenue (GAAP) $375 to $380 million $395 to $410 million Total Revenue (Non-GAAP) $380 to $385 million $400 to $415 million Non-GAAP SG&A Expense $190 to $194 million $195 to $201 million Non-GAAP R&D Expense $14 to $16 million $18 to

  15. Slide 15: Updated Full-Year Guidance

    Updated Ful Total Revenue (GAAP) $375 to $380 million $395 to $410 million ‘Total Revenue (Non-GAAP) $380 to $385 million $400 to $415 million Non-GAAP SG&A Expense $190 to $194 million $195 to $201 million Non-GAAP R&D Expense $14 to $16 million $18 to $23 million Non-GAAP Adjusted EBITDA $104 to $

  16. Slide 16: Summary

    Summary Arthur Higgins, President and Chief Executive Officer

  17. Slide 17: Depomed Committed to Turning Headwinds into Tailwinds

    Depomed Committed to Turning Headwinds into Tailwinds 18 Executing on a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Grow Our Neurology and Pain Businesses and Build a New Specialty Business Leveraging Opportunities to Drive Superior Profitability Committed to Putting the Patient First

  18. Slide 18: Executing on a Clear Strategy

    Executing on a Clear Strategy of Maintain a Strong NUCYNTA Franchise, Grow OuPNeurology and Pain Businesses and Build a New Specialty Business Committed to Putting the Patient First Seoeromen

  19. Slide 19: Note Regarding Use of GAAP and Non-GAAP Financial Measures

    Note Regarding Use of GAAP and Non-GAAP Financial Measures To supplement our financial results presented on a U.S. generally accepted accounting principles, or GAAP, basis, the Company has included information about non-GAAP adjusted earnings, non-GAAP adjusted earnings per share and non-GAAP adjust

  20. Slide 20: GAAP to Non-GAAP Reconciliation: Adjusted Earnings

    GAAP to Non-GAAP Reconciliation Adjusted Earnings 21 RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EARNINGS (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (unaudited) (unaudited) GAAP net loss (15,992) $ (12,894) $

  21. Slide 21: GAAP to Non-GAAP Reconciliation: EBITDA and Adjusted EBITDA

    GAAP to Non-GAAP Reconciliation EBITDA and Adjusted EBIDTA 22 RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA (in thousands) Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (unaudited) (unaudited) GAAP net loss (15,992) $ (12,894) $ (69,392) $ (44,352

  22. Slide 22: Adjusted Information (Three Months Ended September 30, 2017)

    GAAP to Non-GAAP Reconciliation Adjusted Information (Three Months Ended September 30, 2017) 23 Cost of sales Research and development expense Selling, general and administrative expense Restructuring Charges Amortization of intangible assets Interest expense Benefit from (provision for) income taxe

  23. Slide 23: Adjusted Information (Three Months Ended September 30, 2016)

    GAAP to Non-GAAP Reconciliation Adjusted Information (Three Months Ended September 30, 2016) 24 Cost of sales Research and development expense Selling, general and administrative expense Amortization of intangible assets Interest expense Benefit from (provision for) income taxes GAAP as reported 20,

  24. Slide 24: Adjusted Information (Nine Months Ended September 30, 2017)

    GAAP to Non-GAAP Reconciliation Adjusted Information (Nine Months Ended September 30, 2017) 25 Product Sales Cost of sales Research and development expense Selling, general and administrative expense Restructuring Charges Amortization of intangible assets Interest expense Benefit from (provision for

  25. Slide 25: Adjusted Information (Nine Months Ended September 30, 2016)

    GAAP to Non-GAAP Reconciliation Adjusted Information (Nine Months Ended September 30, 2016) 26 Cost of sales Research and development expense Selling, general and administrative expense Amortization of intangible assets Interest expense Benefit from (provision for) income taxes GAAP as reported 64,7

  26. Slide 26: GAAP to Non-GAAP Reconciliation: Earnings Per Share

    GAAP to Non-GAAP Reconciliation Earnings Per Share 27 Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (unaudited) (unaudited) GAAP net loss per share (0.25) $ (0.21) $ (1.11) $ (0.73) $ Conversion from basic shares to diluted shares 0.06 0.05 0.26 0.18 Non-cash i

  27. Slide 27: GAAP to Non-GAAP Reconciliation: Earnings Per Share

    GAAP to Non-GAAP Reconciliation Earnings Per Share [RECONCILIATION OF GAAP NET LOSS PER SHARE TO NON.-GAAP ADJUSTED EARNINGS PER SHARE ‘Three Months Ended ‘Nine Months Ended September 30, September 30, 2017 206 2017 206 (unaudited) (unaudited) 0p netloss per share: $025) $ 2) $ Ga $ (073) ‘Conversio

Depomed — Q3 2017 Earnings Presentation on 6ix